#AUA14 - Poster: Further characterization of the effects of prior or no prior docetaxel therapy on CRPC patients with bone metastases receiving Ra-223 in the phase 3 ALSYMPCA trial

ORLANDO, FL USA (UroToday.com) - Presented by Neal D. Shore,1 Nicholas J. Vogelzang,2 Peter Hoskin,3 Sten Nilsson,4 Robert Coleman,5 Christopher Parker,6 Mona Wahba,7 Karin Staudacher,8 and Oliver Sartor9 at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

aua 2014 ra223 shore poster thumb

1Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA; 2Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; 3Mount Vernon Hospital Cancer Centre, Northwood, UK; 4Karolinska University Hospital, Stockholm, Sweden; 5Weston Park Hospital, Sheffield, UK; 6The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK; 7Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA; 8Algeta ASA (Bayer), Oslo, Norway; 9Tulane Cancer Center, New Orleans, LA, USA

Click HERE to read an exclusive report by a UroToday medical writer

 

 

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland